EU gives go-ahead for Roche's Perjeta with further 2013 approvals to follow

Roche said it anticipates further approvals this year for its targeted breast cancer drug Perjeta (pertuzumab), having secured EU approval for the product to be used in patients with previously untreated HER2-positive metastatic breast cancer (mBC).